LIBERTY LATIN AMERICA ANNOUNCES RETIREMENT OF EDUARDO DIAZ CORONA, SVP AND GENERAL MANAGER OF LIBERTY PUERTO RICO AND USVI
Balan Nair, President and CEO of Liberty Latin America, the parent company of Liberty Puerto Rico and USVI, said, 'I asked Eduardo to come out of retirement to bring his experience and expertise to help us navigate through our customer migration and bring a fresh perspective to our commercial operations. After getting us to this stage, Eduardo decided that it is time for him to step away and enjoy more time with his family. I am so grateful for all his contributions.'
On the appointment of Ponce, Nair continued, 'With Eduardo's departure, I have asked Guillermo to step in as General Manager for our operations in Puerto Rico and the U.S. Virgin Islands on an interim basis. Guillermo is a proven leader and has tremendous commercial and operating experience having led multiple large businesses across Liberty Latin America's footprint. I have no doubt he will add significant value.'
Eduardo commented, 'It has been an honor to serve in this role and be part of an amazing team that is enabling connectivity across Puerto Rico and the U.S. Virgin Islands. I'm incredibly proud of what we've accomplished together, the focus we have brought to putting our customers first, and the positive impact we've had on our communities. As I step away, I have full confidence in the bright future ahead for the business and that Liberty's best days are still to come.'
ABOUT LIBERTY LATIN AMERICA
Liberty Latin America is a leading communications company operating in over 20 countries across Latin America and the Caribbean under the consumer brands BTC, Flow, Liberty, and Más Móvil. The communications and entertainment services that we offer to our residential and business customers in the region include digital video, broadband internet, telephony and mobile services. Our business products and services include enterprise-grade connectivity, data center, hosting and managed solutions, as well as information technology solutions with customers ranging from small and medium enterprises to international companies and governmental agencies. In addition, Liberty Latin America operates a subsea and terrestrial fiber optic cable network that connects over 30 markets in the region.
Liberty Latin America has three separate classes of common shares, which are traded on the NASDAQ Global Select Market under the symbols 'LILA' (Class A) and 'LILAK' (Class C), and on the OTC link under the symbol 'LILAB' (Class B).
For more information, please visit www.lla.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange
MEI Pharma, Inc. (NASDAQ:MEIP) is one of the . On July 18, MEI Pharma, Inc. (NASDAQ:MEIP) announced securities purchase agreements for a private investment in public equity (PIPE) for the sale and purchase of 29,239,767 shares of common stock at a price of $3.42 per share. A modern pharmaceutical laboratory with research scientists working at their desks. The expected aggregate gross proceeds for the transaction come up to approximately $100 million before the exclusion of placement agent fees and other estimated offering expenses. MEI Pharma, Inc. (NASDAQ:MEIP) has plans to use all of the net proceeds for the launch of its treasury strategy focused on Litecoin. The transaction is thus a notable milestone for the company's long-term strategic plan, establishing MEI Pharma, Inc. (NASDAQ:MEIP) as the first and only publicly traded company to adopt Litecoin as a treasury reserve asset. Often referred to as 'silver to Bitcoin's gold,' Litecoin is a peer-to-peer cryptocurrency that Charlie Lee created in October 2011. The integration of Litecoin into its treasury operations has allowed MEI Pharma, Inc. (NASDAQ:MEIP) access to a decentralized monetary asset that complements its cash management framework. MEI Pharma, Inc. (NASDAQ:MEIP) is a pharmaceutical company that develops pharmaceutical compounds. Its programs include Voruciclib and ME-344. While we acknowledge the potential of MEIP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)
ProKidney Corp. (NASDAQ:PROK) is one of the . On July 15, JP Morgan analyst Anupam Rama maintained a neutral stance on ProKidney Corp. (NASDAQ:PROK), giving the stock a Hold rating without a price target. A scientist in a laboratory examining a microscope in the pursuit of cell therapy discoveries. The analyst based the rating on the company's current developments. He acknowledged that ProKidney Corp.'s (NASDAQ:PROK) recent alignment with the FDA for an accelerated approval pathway for rilparencel is an optimistic development and highlights progress in its pivotal PROACT 1 study. However, Rama also stated that the time for the attainment of necessary data for the accelerated approval is longer than previously expected, as key data is expected to roll out in Q2 2027. The analyst thus reasoned that although there have been notable optimistic updates in the trial, the extended timeline may weigh on investor sentiment, warranting a cautious outlook on the stock. ProKidney Corp. (NASDAQ:PROK) is a clinical-stage biotechnology company that develops a proprietary cell therapy platform. The company's emphasis is on chronic kidney disease treatment, shifting focus to kidney function restoration to delay or stop the progression of CKD. While we acknowledge the potential of PROK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target
Vor Biopharma Inc. (NASDAQ:VOR) is one of the . In a report released on June 30, Swayampakula Ramakanth from H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR) to a Buy with a price target of $3.00. The analyst based the optimistic outlook on the company's growth potential and strategic advancements. A scientist in a lab coat looking through a microscope at a petri dish of hematopoietic stem cells. Vor Biopharma Inc. (NASDAQ:VOR) recently announced an exclusive license agreement with RemeGen Co. for the development and commercialization of telitacicept in regions outside of Greater China. Telitacicept is a promising recombinant fusion protein and has already exhibited clinical success, attaining marketing approvals in China for a number of conditions, including generalized myasthenia gravis, systemic lupus nephritis, and rheumatoid arthritis. The analyst further reasoned that the financial structure of the agreement lends Vor Biopharma Inc. (NASDAQ:VOR) financial strength because it includes upfront payments and potential milestone payments. Vor Biopharma Inc. (NASDAQ:VOR) is a clinical-stage cell therapy company that develops cell therapies for the treatment of cancer. It combines therapies with a novel patient engineering approach to provide a single company solution for hematological malignancies. While we acknowledge the potential of VOR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
